Infarct-avid imaging: usefulness, problems and limitations

  • Ernest K. J. Pauwels
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 133)


Physicians working in coronary care units may face problems in diagnosing infarction in patients with electrocardiographic conduction disturbances or when electrocardiographic data are in conflict with enzyme data. Under such circumstances, noninvasive diagnostic imaging may be of help.


Acute Myocardial Infarction Myocardial Blood Flow Coronary Care Unit Myocardial Scintigraphy Transmural Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wynne J, Holman BL, Lesch M. Myocardial scintigraphy by infarct-avid radiotracers. Prog Cardiovasc Dis 1978; 20: 243–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Perez LA, Hayt DB, Freeman LM. Localization of myocardial disorders other than infarction with 99mTc-labeled phosphate agents. J Nucl Med 1976; 17: 241–6.PubMedGoogle Scholar
  3. 3.
    Joseph SP, Pereira-Prestes AV, Ell PJ, Donaldson R, Sommerville W, Emanuel RW. Value of positive myocardial infarction imaging in coronary care units. Br Med J 1979; 1: 372–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Tetalman MR, Foley LC, Spencer CP, Bishop SP. A critical review of the efficacy of 99mTc pyrophosphate in detecting myocardial infarction in 103 patients. Radiology 1977; 124:431–2.PubMedGoogle Scholar
  5. 5.
    Parkey RW, Kulkarni PV, Lewis SE et al. Effect of coronary blood flow and site of injection of Tc-99m PPi detection of early canine myocardial infarcts. J Nucl Med 1981; 22: 133–7.PubMedGoogle Scholar
  6. 6.
    Izquierdo C, Devous MD Sr, Nicod P et al. A comparison of infarct identification with technetium-99m pyrophosphate and staining with triphenyl tetrazolium chloride. J Nucl Med 1983; 24: 492–7.PubMedGoogle Scholar
  7. 7.
    Buja LM, Parkey RW, Stokely EM, Bonte FJ, Willerson JT. Pathophysiology of technetium-99m stannous pyrophosphate and thallium-201 scintigraphy of acute anterior myocardial infarcts in dogs. J Clin Invest 1976; 57: 1508–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Dewanjee MK, Kahn PC. Mechanism of localization of 99mTc-labeled pyrophosphate and tetracycline in infarcted myocardium. J Nucl Med 1976; 17: 639–46.PubMedGoogle Scholar
  9. 9.
    Buja LM, Tofe AJ, Kulkarni PV et al. Sites and mechanisms of localization of technetium-99m phosphorous radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest2 1977; 60: 724–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Berman DS, Amsterdam EA, Hines HH et al. New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction. Am J Cardiol 1977; 39: 341–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Cowley MJ, Mantle JA, Rogers WJ, Russell RO Jr, Rackley CE, Logic JR. Technetium-99m stannous pyrophophate myocardial scintigraphy. Reliability and limitations in assessment of acute myocardial infarction. Circulation 1977; 56: 192–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Poliner LR, Buja LM, Parkey RW, Bonte FJ, Willerson JT. Clinicopathologic findings in 52 patients studied by technetium-99m stannous pyrophosphate myocardial scintigraphy. Circulation 1979; 59: 257–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Khaw BA, Fallon JT, Strauss HW, Haber E. Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid. Science 1980; 209: 295–7.CrossRefGoogle Scholar
  14. 14.
    Haber E. Immunological probes in cardiovascular disease. Br Heart J 1982; 47: 1–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Khaw BA, Yasuda T, Gold HK et al. Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. J Nucl Med 1987; 28: 1671–8.PubMedGoogle Scholar
  16. 16.
    Nakata T, Sakakibara T, Noto T et al. Myocardial distribution of indium-111-antimyosin Fab in acute inferior and right ventricular infarction: comparison with technetium-99m-pyrophosphate imaging and histologic examination. J Nucl Med 1991; 32: 865–7.PubMedGoogle Scholar
  17. 17.
    Fishbein MC, MacLean D, Maroko PR. The histopathologic evolution of myocardial infarction. Chest 1978; 73: 843–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Tamaki N, Yamada T, Matsumori A et al. Indium-111-antimyosin antibody imaging for detecting different stages of myocardial infarction; comparison with technetium-99m-pyrophosphate imaging. J Nucl Med 1990; 31: 136–42.PubMedGoogle Scholar
  19. 19.
    Liu XJ, Jain D, Senior R, Broadhurst P, Lahiri A. 111In-antimyosin antibody imaging for detection of myocardial infarction: a quantitative approach. Nucl Med Commun 1990; 11: 667–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Morguet AJ, Munz DL, Kreuzer H, Emrich D. Immunoscintigraphy with 111In antimyosin Fab. Nucl Med Commun 1990; 11: 727–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Olson HG, Lyons KP, Aronow WS, Kuperus J, Orlando J, Hughes D. Prognostic value of a persistently positive technetium-99m stannous pyrophosphate myocardial scintigram after myocardial infarction. Am J Cardiol 1979; 43: 889–98.PubMedCrossRefGoogle Scholar
  22. 22.
    Croft CH, Rude RE, Lewis SE et al. Comparison of left ventricular function and infarct size in patients with and without persistently positive technetium-99m pyrophosphate myocardial scintigrams after myocardial infarction: analysis of 357 patients1. Am J Cardiol 1984; 53: 421–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Orlandi C, Crane PD, Edwards S et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med 1991; 32:263–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • Ernest K. J. Pauwels

There are no affiliations available

Personalised recommendations